GTBP
- GT Biopharma, Inc.
()
Overview
Company Summary
GT Biopharma, Inc. (GTBP) is a biotechnology company that primarily focuses on developing novel immuno-oncology treatments. The company utilizes its proprietary Tri-specific Killer Engager (TriKE) platform to develop innovative therapies for various types of cancer.
The TriKE platform developed by GT Biopharma combines the targeting ability of antibodies and the cytotoxic power of natural killer (NK) cells. This unique technology enhances the body's immune system to effectively target and kill cancer cells. By engaging the patient's immune system, GT Biopharma aims to develop safer and more effective treatments with reduced side effects compared to conventional chemotherapy.
GT Biopharma's pipeline includes a diverse range of TriKE-based therapeutic candidates targeting different cancer types. These candidates are designed to address challenging and hard-to-treat cancers such as acute myeloid leukemia (AML), multiple myeloma, and prostate cancer.
One of GT Biopharma's lead products is GTB-3550, an NK cell-engaging TriKE designed to treat AML and myelodysplastic syndrome (MDS). GTB-3550 has shown promising results in early clinical trials, demonstrating its potential as a targeted therapy for these types of blood cancers.
In addition to its TriKE platform, GT Biopharma is also involved in research collaborations and partnerships to explore other innovative approaches in immunotherapy and gene editing technologies. The company constantly strives to advance its understanding of cancer biology and develop groundbreaking treatments for patients in need.
Overall, GT Biopharma aims to revolutionize cancer therapy by leveraging the power of the immune system with their TriKE platform and developing novel therapies that can effectively combat various types of cancer.